Hep C Knowledge Bank

Marcellin P. et al. (2012) Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opinion on Drug Safety, 11(6):901-909.

Hajarizadeh B. et al. (2012) Case definitions for acute hepatitis C virus infection: a systematic review. Journal of Hepatology, 57(6):1349-1360.

Gu S. et al. (2012) Core antigen tests for hepatitis C virus: a meta-analysis. Molecular Biology Reports, 39(8):8197-8208.

Ford N. et al. (2012) Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bulletin of the World Health Organization, 90(7):540-550.

Dang SS. et al. (2012) Telaprevir for chronic hepatitis C with genotype 1: a meta-analysis. Hepato-Gastroenterology, 59(114):461-468.

Coppola N. et al. (2012) Efficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infectious Diseases, 12:357.

Chang MH. et al. (2012) Boceprevir: a protease inhibitor for the treatment of hepatitis C. Clinical Therapeutics, 34(10):2021-2038.

Tohme, R. A., & Holmberg, S. D. (2012). Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clinical infectious diseases, 54(8), 1167-1178.

Miller. et. al. (2012). The ongoing impacts of hepatitis c – a systematic narrative review of the literature. BMC Public Health.

Alghamdi AS. et. al. (2012). SASLT practice guidelines for the management of hepatitis C virus infection: summary of recommendations. Saudi Journal of Gastroenterology, 18(5): 293-298.

 

 

Pages